` KZIA (Kazia Therapeutics Ltd) vs S&P 500 Comparison - Alpha Spread

KZIA
vs
S&P 500

Over the past 12 months, KZIA has underperformed S&P 500, delivering a return of -51% compared to the S&P 500's +17% growth.

Stocks Performance
KZIA vs S&P 500

Loading
KZIA
S&P 500
Add Stock

Performance Gap
KZIA vs S&P 500

Loading
KZIA
S&P 500
Difference
www.alphaspread.com

Performance By Year
KZIA vs S&P 500

Loading
KZIA
S&P 500
Add Stock

Competitors Performance
Kazia Therapeutics Ltd vs Peers

S&P 500
KZIA
ABBV
CYTH
AMGN
GILD
Add Stock

Kazia Therapeutics Ltd
Glance View

Market Cap
11m USD
Industry
Biotechnology

Kazia Therapeutics Ltd. engages in the development of pharmaceutical drug. The company is headquartered in Sydney, New South Wales. The firm collaborates with clinicians, scientists, and researchers across the world for the development of cancer treatment. The Company’s product candidates include Paxalisib and EVT801. Paxalisib (GDC-0084) is invented by Genentech, Inc (South San Francisco, CA). Genentech, Inc is a developer of new cancer medicines across the world. The firm entered into a license agreement with Genentech. EVT801 targets angiogenesis, the formation of new blood vessels around a tumor. EVT801 is invented by Sanofi SA (Paris, France), and licensed to Evotec SE (Hamburg, Germany). The firm entered into a license agreement with Evotec. EVT801 is ready for Phase I clinical trial.

KZIA Intrinsic Value
Not Available
Back to Top